Ignite Creation Date:
2024-05-06 @ 1:40 AM
Last Modification Date:
2024-10-26 @ 11:08 AM
Study NCT ID:
NCT01878955
Status:
UNKNOWN
Last Update Posted:
2018-03-01
First Post:
2013-05-14
Brief Title:
The Use Of AMH for the Discrimination of Polycystic and Multicystic Ovaries in Nonhyperandrogenic Patients
Sponsor:
Izmir Katip Celebi University
Organization:
Izmir Katip Celebi University
Study Overview
Official Title:
Elevation of AMH Resulted From Ovarian Structural Properties or Effects of Gonadotropines
Status:
UNKNOWN
Status Verified Date:
2018-02
Last Known Status:
ACTIVE_NOT_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
AMH is a member of the transforming growth factor family It is produced by the granulosa cells from 36th weeks of pregnancyOvarian granulosa cells are the only source of the antimüllerian hormone AMH production continues until response to exogenous FSH occurs and follicles reach 4-6 mm in diameterThe number of follicles in patients with polycystic ovaries are 2-6 times higher than normal women Serum AMH levels are 2-3 times higher in patients with PCOS The cause of elevated serum AMH levels in patients with PCOS is unknown There are data showing elevated serum AMH level is due to the increase in the number of follicles 2-8 mm in diameter Although there is no precise definition multicystic ovarian is defined by the presence of more than six follicles 4-9 mm in diameter and mixed morphologically with PCO PCO and multicystic ovaries are distinguished by the absence of the increase in stroma volumeThe aim of this study is to investigate whether there is a difference of serum AMH levels between patients with PCO or multicystic ovaries A primary goal is to investigate the usability of AMH as a marker besides ultrasound for discrimination of nonhyperandrogenic patients with PCO or multicystic ovaries
Detailed Description:
It is planned to compare the values of FSHLH AMH and 75 gr OGTT between 20 patients diagnosed as PCOS according to the AES-Rotterdam criteria and 20 patients with multicystic ovarian structure but do not provide the PCOS-D3 criteria The second purpose of this study is to investigate the mechanism that leads to the elevation of AMH in patients with PCOS and to reveal the effects of intraovarian paracrine factorsinsulin resistance and FSH LH
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None